ixlayer’s unified direct-to-patient platform, helps biopharma transform the patient experience
Simplify and Accelerate the Connection to Care
Scheduled a visit with a
physician after receiving
abnormal lab results.
Patient activation increase
vs. traditional outreach.
Increase in diagnostic testing compliance vs. U.S benchmark.
Intuitive interface and simple one-time sign-on supports continuous patient engagement
Connection to PCPs and Specialists virtually and in-person accelerates the connection to care
Deep partnerships across the healthcare ecosystem support multiple, differentiated patient journeys
Proactive care and convenient health access drive earlier interventions and help patients achieve their health goals
ixlayer connects a vast health ecosystem for a convenient and seamless virtual patient experience. Users can screen for health conditions, easily monitor their health, seamlessly connect with care providers and have medication delivered all without leaving our platform.
Seamlessly integrate with a vast health ecosystem and launch services to support specific brand initiatives.
Built on a secure technological backbone, our flexible product design enables rapid deployment and scalability, and allows us to configure solutions to best meet our clients’ needs across multiple therapeutic areas.
Telehealth services, lab testing, Rx fulfillment, benefits verification, and more can be implemented across a patient journey designed to support different patient needs and priorities.
We offer our clients the opportunity to deliver a personalized healthcare journey to all patients with our fully integrated, configurable platform. We have powered over 1,100 nationwide programs and enabled over 4 million patient care journeys for greater operational efficiency, patient access, and improved outcomes.
Across the biopharma industry,
our clients value our speed, our service and our solutions.
The latest research, news and expert opinion keeping you up to date on DTP industry innovation.
New Performance Data Shows Why Pharma Is Reallocating Spend Toward Direct-to-Patient Care Pharmaceutical brands are increasingly shifting investment toward direct-to-patient
Fierce Pharma highlights pharma’s shift toward direct-to-patient models A recent Fierce Pharma article examines how pharmaceutical companies are increasingly experimenting
MediaPost Highlights Need to Move From Awareness to Action “Pharma Ads Losing Effectiveness? Try Direct-To-Patient Programs” A recent MediaPost article
Fierce Pharma publisher Rebecca Willumson caught up with ixlayer’s General Manager of Biopharma, Matthew Walsh, at Digital Pharma East 2025
Pharma’s Reputation Could Get a Boost If Digital Health Services Become the Rule, Not the Exception A new survey conducted
ixlayer Expands Access to Evidence-Based Dermatological Care Nationwide Patients Can Now Connect with Expert Clinicians through the SkinLink Platform to
New Performance Data Shows Why Pharma Is Reallocating Spend Toward Direct-to-Patient Care Pharmaceutical brands are increasingly shifting investment toward direct-to-patient
Fierce Pharma highlights pharma’s shift toward direct-to-patient models A recent Fierce Pharma article examines how pharmaceutical companies are increasingly experimenting
MediaPost Highlights Need to Move From Awareness to Action “Pharma Ads Losing Effectiveness? Try Direct-To-Patient Programs” A recent MediaPost article
